Cargando…

Current Progress in Vascular Engineering and Its Clinical Applications

Coronary heart disease (CHD) is caused by narrowing or blockage of coronary arteries due to atherosclerosis. Coronary artery bypass grafting (CABG) is widely used for the treatment of severe CHD cases. Although autologous vessels are a preferred choice, healthy autologous vessels are not always avai...

Descripción completa

Detalles Bibliográficos
Autores principales: Jouda, Hatem, Larrea Murillo, Luis, Wang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834640/
https://www.ncbi.nlm.nih.gov/pubmed/35159302
http://dx.doi.org/10.3390/cells11030493
_version_ 1784649236500971520
author Jouda, Hatem
Larrea Murillo, Luis
Wang, Tao
author_facet Jouda, Hatem
Larrea Murillo, Luis
Wang, Tao
author_sort Jouda, Hatem
collection PubMed
description Coronary heart disease (CHD) is caused by narrowing or blockage of coronary arteries due to atherosclerosis. Coronary artery bypass grafting (CABG) is widely used for the treatment of severe CHD cases. Although autologous vessels are a preferred choice, healthy autologous vessels are not always available; hence there is a demand for tissue engineered vascular grafts (TEVGs) to be used as alternatives. However, producing clinical grade implantable TEVGs that could healthily survive in the host with long-term patency is still a great challenge. There are additional difficulties in producing small diameter (<6 mm) vascular conduits. As a result, there have not been TEVGs that are commercially available. Properties of vascular scaffolds such as tensile strength, thrombogenicity and immunogenicity are key factors that determine the biocompatibility of TEVGs. The source of vascular cells employed to produce TEVGs is a limiting factor for large-scale productions. Advanced technologies including the combined use of natural and biodegradable synthetic materials for scaffolds in conjunction with the use of mesenchyme stem cells or induced pluripotent stem cells (iPSCs) provide promising solutions for vascular tissue engineering. The aim of this review is to provide an update on various aspects in this field and the current status of TEVG clinical applications.
format Online
Article
Text
id pubmed-8834640
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88346402022-02-12 Current Progress in Vascular Engineering and Its Clinical Applications Jouda, Hatem Larrea Murillo, Luis Wang, Tao Cells Review Coronary heart disease (CHD) is caused by narrowing or blockage of coronary arteries due to atherosclerosis. Coronary artery bypass grafting (CABG) is widely used for the treatment of severe CHD cases. Although autologous vessels are a preferred choice, healthy autologous vessels are not always available; hence there is a demand for tissue engineered vascular grafts (TEVGs) to be used as alternatives. However, producing clinical grade implantable TEVGs that could healthily survive in the host with long-term patency is still a great challenge. There are additional difficulties in producing small diameter (<6 mm) vascular conduits. As a result, there have not been TEVGs that are commercially available. Properties of vascular scaffolds such as tensile strength, thrombogenicity and immunogenicity are key factors that determine the biocompatibility of TEVGs. The source of vascular cells employed to produce TEVGs is a limiting factor for large-scale productions. Advanced technologies including the combined use of natural and biodegradable synthetic materials for scaffolds in conjunction with the use of mesenchyme stem cells or induced pluripotent stem cells (iPSCs) provide promising solutions for vascular tissue engineering. The aim of this review is to provide an update on various aspects in this field and the current status of TEVG clinical applications. MDPI 2022-01-31 /pmc/articles/PMC8834640/ /pubmed/35159302 http://dx.doi.org/10.3390/cells11030493 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jouda, Hatem
Larrea Murillo, Luis
Wang, Tao
Current Progress in Vascular Engineering and Its Clinical Applications
title Current Progress in Vascular Engineering and Its Clinical Applications
title_full Current Progress in Vascular Engineering and Its Clinical Applications
title_fullStr Current Progress in Vascular Engineering and Its Clinical Applications
title_full_unstemmed Current Progress in Vascular Engineering and Its Clinical Applications
title_short Current Progress in Vascular Engineering and Its Clinical Applications
title_sort current progress in vascular engineering and its clinical applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834640/
https://www.ncbi.nlm.nih.gov/pubmed/35159302
http://dx.doi.org/10.3390/cells11030493
work_keys_str_mv AT joudahatem currentprogressinvascularengineeringanditsclinicalapplications
AT larreamurilloluis currentprogressinvascularengineeringanditsclinicalapplications
AT wangtao currentprogressinvascularengineeringanditsclinicalapplications